Clinical Trials Directory

Trials / Completed

CompletedNCT02927223

Atropine in Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

Pretreatment With Atropine to Reduce Exercise-triggered Ventricular Ectopy in Patients With Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
6 (actual)
Sponsor
Vanderbilt University · Academic / Other
Sex
All
Age
6 Years
Healthy volunteers
Not accepted

Summary

To test the hypothesis that increasing the sinus node rate with atropine treatment prior to exercise will reduce exercise-triggered ventricular ectopy compared to baseline in patients with CPVT.

Detailed description

This is a prospective cross-over trial that will enroll eligible patients with CPVT and perform a baseline treadmill exercise tolerance test (ETT) followed by a repeat treadmill ETT with I.V. atropine administered immediately prior to exercise. Atropine is a parasympathetic blocker and results in sinus tachycardia, which is expected to reduce the diastolic interval thereby reducing delayed after depolarizations and ventricular ectopy compared to baseline. Both ETTs will be performed on the same day with two hours of rest scheduled between ETTs. The primary analysis will be a paired comparison of the number of ventricular ectopic beats recorded during exercise (and recovery) at baseline and following pre-treatment with atropine. Secondary endpoints will include the presence of ventricular ectopy (yes/no), complex ventricular ectopy (couplets or greater, yes/no), and the number of runs of complex ventricular ectopy.

Conditions

Interventions

TypeNameDescription
DRUGAtropine
PROCEDUREExercise treadmill test

Timeline

Start date
2016-10-01
Primary completion
2019-02-01
Completion
2019-02-01
First posted
2016-10-06
Last updated
2020-01-28
Results posted
2020-01-28

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT02927223. Inclusion in this directory is not an endorsement.